The therapeutic potential of stem cell-derived exosomes in the ulcerative colitis and colorectal cancer

Stem Cell Res Ther. 2022 Apr 1;13(1):138. doi: 10.1186/s13287-022-02811-5.

Abstract

Background: Mesenchymal stem cells (MSCs) therapy is a novel treatment strategy for cancer and a wide range of diseases with an excessive immune response such as ulcerative colitis (UC), due to its powerful immunomodulatory properties and its capacity for tissue regeneration and repair. One of the promising therapeutic options can focus on MSC-secreted exosomes (MSC-Exo), which have been identified as a type of paracrine interaction. In light of a wide variety of recent experimental studies, the present review aims to seek the recent research advances of therapies based on the MSC-Exo for treating UC and colorectal cancer (CRC).

Methods: A systematic literature search in MEDLINE, Scopus, and Google Scholar was performed from inception to December 2021 using the terms [("colorectal cancer" OR "bowel cancer" OR "colon cancer" OR "rectal cancer") AND (exosome) AND (stem cell) AND ("inflammatory bowel disease" OR "Crohn's disease" OR "colitis")] in titles and abstracts.

Findings: Exosomes derived from various sources of MSCs, including human umbilical cord-derived MSCs (hUC-MSCs), human adipose-derived MSCs (hAD-MSCs), human bone marrow-derived MSCs (hBM-MSCs), and olfactory ecto-MSCs (OE-MSCs), have shown the protective role against UC and CRC. Exosomes from hUC-MSCs, hBM-MSCs, AD-MSCs, and OE-MSCs have been found to ameliorate the experimental UC through suppressing inflammatory cells including macrophages, Th1/Th17 cells, reducing the expression of proinflammatory cytokines, as well as inducing the anti-inflammatory function of Treg and Th2 cells and enhancing the expression of anti-inflammatory cytokines. In addition, hBM-MSC-Exo and hUC-MSC-Exo containing tumor-suppressive miRs (miR-3940-5p/miR-22-3p/miR-16-5p) have been shown to suppress proliferation, migration, and invasion of CRC cells via regulation of RAP2B/PI3K/AKT signaling pathway and ITGA2/ITGA6.

Key messages: The MSC-Exo can exert beneficial effects on UC and CRC through two different mechanisms including modulating immune responses and inducing anti-tumor responses, respectively.

Keywords: Colorectal cancer; Exosome; Mesenchymal stem cells; Ulcerative colitis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative* / therapy
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / therapy
  • Exosomes* / metabolism
  • Humans
  • Mesenchymal Stem Cells* / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • rap GTP-Binding Proteins / metabolism

Substances

  • RAP2B protein, human
  • rap GTP-Binding Proteins